These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
212 related articles for article (PubMed ID: 17024116)
1. Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis. Gutiérrez NC; Castellanos MV; Martín ML; Mateos MV; Hernández JM; Fernández M; Carrera D; Rosiñol L; Ribera JM; Ojanguren JM; Palomera L; Gardella S; Escoda L; Hernández-Boluda JC; Bello JL; de la Rubia J; Lahuerta JJ; San Miguel JF; Leukemia; 2007 Jan; 21(1):143-50. PubMed ID: 17024116 [TBL] [Abstract][Full Text] [Related]
2. The t(11;14)(q13;q32) translocation as a poor prognostic parameter for autologous stem cell transplantation in myeloma patients with extramedullary plasmacytoma. Shin HJ; Kim K; Lee JJ; Song MK; Lee EY; Park SH; Kim SH; Jang MA; Kim SJ; Chung JS Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):227-35. PubMed ID: 25812994 [TBL] [Abstract][Full Text] [Related]
3. Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation. Neben K; Jauch A; Bertsch U; Heiss C; Hielscher T; Seckinger A; Mors T; Müller NZ; Hillengass J; Raab MS; Ho AD; Hose D; Goldschmidt H Haematologica; 2010 Jul; 95(7):1150-7. PubMed ID: 20220069 [TBL] [Abstract][Full Text] [Related]
4. Chromosome 1p21 deletion is a novel prognostic marker in patients with multiple myeloma. Chang H; Ning Y; Qi X; Yeung J; Xu W Br J Haematol; 2007 Oct; 139(1):51-4. PubMed ID: 17854306 [TBL] [Abstract][Full Text] [Related]
5. 1p21 deletions are strongly associated with 1q21 gains and are an independent adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma. Chang H; Qi X; Jiang A; Xu W; Young T; Reece D Bone Marrow Transplant; 2010 Jan; 45(1):117-21. PubMed ID: 19448682 [TBL] [Abstract][Full Text] [Related]
6. Genetic risk identifies multiple myeloma patients who do not benefit from autologous stem cell transplantation. Chang H; Qi XY; Samiee S; Yi QL; Chen C; Trudel S; Mikhael J; Reece D; Stewart AK Bone Marrow Transplant; 2005 Nov; 36(9):793-6. PubMed ID: 16113669 [TBL] [Abstract][Full Text] [Related]
7. Increased copy number of the interleukin-6 receptor gene is associated with adverse survival in multiple myeloma patients treated with autologous stem cell transplantation. Kim SY; Min HJ; Park HK; Oh B; Kim TY; She CJ; Hwang SM; Kim M; Kim HK; Kim I; Yoon SS; Park S; Kim BK; Lee JH; Lee DS; Biol Blood Marrow Transplant; 2011 Jun; 17(6):810-20. PubMed ID: 21220034 [TBL] [Abstract][Full Text] [Related]
8. Deletion of the short arm of chromosome 1 (del 1p) is a strong predictor of poor outcome in myeloma patients undergoing an autotransplant. Qazilbash MH; Saliba RM; Ahmed B; Parikh G; Mendoza F; Ashraf N; Hosing C; Flosser T; Weber DM; Wang M; Couriel DR; Popat U; Kebriaei P; Alousi AM; Anderlini P; Naeem RC; Champlin RE; Giralt SA Biol Blood Marrow Transplant; 2007 Sep; 13(9):1066-72. PubMed ID: 17697969 [TBL] [Abstract][Full Text] [Related]
9. Negative prognostic significance of two or more cytogenetic abnormalities in multiple myeloma patients treated with autologous stem cell transplantation. Greslikova H; Zaoralova R; Filkova H; Nemec P; Oltova A; Kupska R; Rudolecka P; Smetana J; Pour L; Zahradova L; Krejci M; Buchler T; Adam Z; Hajek R; Kuglik P Neoplasma; 2010; 57(2):111-7. PubMed ID: 20099973 [TBL] [Abstract][Full Text] [Related]
10. Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma. Schilling G; Hansen T; Shimoni A; Zabelina T; Pérez-Simón JA; Gutierrez NC; Bethge W; Liebisch P; Schwerdtfeger R; Bornhäuser M; Otterstetter S; Penas EM; Dierlamm J; Ayuk F; Atanackovic D; Bacher U; Bokemeyer C; Zander A; San Miguel J; Nagler A; Kröger N Leukemia; 2008 Jun; 22(6):1250-5. PubMed ID: 18418408 [TBL] [Abstract][Full Text] [Related]
11. Complex karyotype and translocation t(4;14) define patients with high-risk newly diagnosed multiple myeloma: results of CMG2002 trial. Nemec P; Zemanova Z; Kuglik P; Michalova K; Tajtlova J; Kaisarova P; Oltova A; Filkova H; Holzerova M; Balcarkova J; Jarosova M; Rabasova J; Hruba M; Spicka I; Gregora E; Adam Z; Scudla V; Maisnar V; Schutzova M; Hajek R; Leuk Lymphoma; 2012 May; 53(5):920-7. PubMed ID: 22023516 [TBL] [Abstract][Full Text] [Related]
12. The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant. Chang H; Sloan S; Li D; Zhuang L; Yi QL; Chen CI; Reece D; Chun K; Keith Stewart A Br J Haematol; 2004 Apr; 125(1):64-8. PubMed ID: 15015970 [TBL] [Abstract][Full Text] [Related]
13. Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma. Rajkumar S; Fonseca R; Lacy M; Witzig T; Lust J; Greipp P; Therneau T; Kyle R; Litzow M; Gertz M Bone Marrow Transplant; 1999 Sep; 24(5):497-503. PubMed ID: 10482933 [TBL] [Abstract][Full Text] [Related]
14. Combinations of cytogenetics and international scoring system can predict poor prognosis in multiple myeloma after high-dose chemotherapy and autologous stem cell transplantation. Inamoto Y; Kurahashi S; Imahashi N; Fukushima N; Adachi T; Kinoshita T; Tsushita K; Miyamura K; Naoe T; Sugiura I Am J Hematol; 2009 May; 84(5):283-6. PubMed ID: 19338045 [TBL] [Abstract][Full Text] [Related]
15. Genomic aberrations and survival of patients with light-chain-only multiple myeloma undergoing autologous stem cell transplantation. Jiang N; Qi C; Trieu Y; Reece D; Chang H Biol Blood Marrow Transplant; 2011 Dec; 17(12):1790-5. PubMed ID: 21658460 [TBL] [Abstract][Full Text] [Related]